Shigella Vaccines Market Growth Accelerated by Rising Morbidity Rates
Shigella vaccines have gained popularity owing to the growing prevalence of Shigella infection globally. Shigella bacteria causes shigellosis, which is a gastrointestinal infection commonly known as bacillary dysentery. Shigella infection leads to abdominal pain, diarrhea with possible traces of blood or mucus, fever, nausea, and vomiting. Shigella vaccines help prevent Shigella infection and associated complications.
The global Shigella Vaccines Market is estimated to be
valued at US$ 574.20 mn in 2023 and is expected to exhibit a CAGR of 6.4% over
the forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
Rising morbidity rates have accelerated the growth of the Shigella vaccines
market over the forecast period. According to the World Health Organization
(WHO), Shigella causes an estimated 80-165 million cases and causes around
69,000 deaths annually worldwide, with majority of deaths occurring in low-income
countries and among children under five years of age. In the U.S., Shigella
causes approximately 500,000 cases annually. Growing disease prevalence has
boosted awareness regarding the need for effective prevention of Shigella
infection, thereby driving the demand for Shigella vaccines over the forecast
period.
Segment
Analysis
The global Shigella
vaccines market is dominated by the multivalent Shigella vaccines segment.
These vaccines provide protection against multiple Shigella serotypes that are
responsible for shigellosis such as Shigella flexneri and Shigella sonnei.
These multivalent Shigella vaccines are more effective as they offer wider
protection compared to monovalent Shigella vaccines that protect against only
one serotype. Therefore, the multivalent Shigella vaccines segment is currently
dominating the market.
Key Takeaways
The global Shigella vaccines market is expected to witness high growth over the
forecast period of 2023-2030.
Regional analysis: North America currently dominates the market
due to high research activities for shigellosis vaccines and presence of major
players. However, Asia Pacific region is expected to witness fastest growth due
to increasing incidence of shigellosis infections in developing Asian
countries.
Asia Pacific region is poised to witness fastest growth in the Shigella
vaccines market led by China, India, and other Southeast Asian countries. This
is attributed to rising healthcare awareness and improving healthcare
infrastructure in emerging economies. Additionally, high prevalence of
shigellosis infections especially in densely populated areas creates
significant demand for preventive vaccines.
Comments
Post a Comment